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Background: There is an increased prevalence of hypothyroidism in chronic kidney
disease (CKD) patients as the glomerular ﬁltration rate falls. However, there is a
paucity of Indian data in this respect.
Methods: A cross-sectional analysis was performed based on the database of the
information system of a tertiary care hospital in northern India to retrieve results of
nephrology CKD outpatients (> 18 years of age) from September 2013 to October
2015 to determine the prevalence of hypothyroidism in the nonedialysis-dependent
CKD population. Overt hypothyroidism was deﬁned by a thyroid-stimulating hor-
mone (TSH) level > 5.5 mIU/L and free T4 level < 0.89 ng/dL with clinical symptoms.
Subclinical hypothyroidism was deﬁned by a TSH level > 5.5 mIU/L and a free T4
level  0.89 ng/dL.
Results: Among 1,863 CKD patients, 358 patients underwent biochemical analysis
for hypothyroidism. Among these, 143 had biochemical subclinical hypothyroidism
and 59 had overt hypothyroidism. Patients in the overt hypothyroid group had
signiﬁcantly higher TSH levels and a lower free T4 level than those in the non-
hypothyroid group. Patients with hypothyroidism (both clinical and subclinical) had
signiﬁcantly lower serum albumin and serum calcium levels than those in the non-
hypothyroid group. Intact parathyroid hormone was also signiﬁcantly higher in the
hypothyroid groups. An increased prevalence of hypothyroidism was observed in
patients with a reduction in the glomerular ﬁltration rate.
Conclusion: There is growing evidence of increased prevalence of hypothyroidism in
dialysis-independent CKD patients. A number of ﬁndings such as lower serum al-
bumin, serum calcium, and hemoglobin levels and higher intact parathyroid hor-
mone levels are seen in this group. Speciﬁc treatment can help improve these. Hence,
there is a need to formulate guidelines to screen this population for hypothyroidism.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ti Khand, Gomti Nagar,
636@gmail.com.
ty of Nephrology. Published b
/4.0/).Introduction
It has been shown that in chronic kidney disease (CKD), as
the glomerular ﬁltration rate (GFR) falls, there is a higher
possibility of developing clinical and subclinical hypothyroid-
ism (SCH) [1]. With falling GFR, there are a number of abnor-
malities developing in the thyroid gland at both structural and
functional level. There is an increase in thyroid volume as they Elsevier. This is an open access article under the CC BY-NC-ND license
Figure 1. Flow chart of study design.
CKD, chronic kidney disease; FT4, free T4; OPD, out patient department;
TSH, thyroid-stimulating hormone.
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population, which is possibly an adaptation of the chronic in-
ﬂammatory andmalnourished state prevalent in these patients.
The overlapping features of CKD and hypothyroidism make it
all themore challenging for the clinician to timely diagnose and
treat it. In spite of the growing volume of information, there is a
dearth of Indian data with respect to SCH and overt hypothy-
roid prevalence in patients with CKD who are not dialysis
dependent. To gain further insight into this, we conducted a
survey of the CKD population visiting this tertiary care center to
determine the prevalence of hypothyroidism in the non-
edialysis-dependent CKD population.
Methods
A cross-sectional analysis based on the database of the in-
formation system of a tertiary care hospital in northern India to
retrieve results of nephrology CKD outpatients (> 18 years of
age) referred to this tertiary care center from September 2013
to October 2015 was conducted.
Serum thyroid-stimulating hormone (TSH) and free T4 (FT4)
concentrations were quantiﬁed by direct chemiluminescence
using acridinium ester technology on the ADVIA Centaur XP
analyzer (Siemens Healthcare, Tarrytown, New York, USA).
Functional sensitivity for TSH and FT4 was quoted by the
manufacturer as 0.004e150 mIU/L and 0.1e12.0 ng/dL, respec-
tively. Reference values in our laboratory were 0.35e5.5 mIU/L
for TSH and 0.89e1.78 ng/dL for FT4, respectively. The estimated
GFR (eGFR) was calculated using the 2009 chronic kidney
disease Epidemiology Collaboration creatinine equation, and
the stages of CKD were deﬁned according to the kidney disease
improving global outcome guidelines for evaluation of CKD.
Overt hypothyroidism would be deﬁned by a TSH level
> 5.5 mIU/L and a FT4 level < 0.89 ng/dL with clinical symp-
toms. SCH would be deﬁned by a TSH level > 5.5 mIU/L and a
FT4 level  0.89 ng/dL (the lower limit of the normal range).
Inclusion criterion was all CKD patients (> 18 years of age)
not requiring long-term dialysis with TSH levels > 5.5 mIU/L.
Exclusion criteria were as follows: subjects younger than
18 years, pregnant women, subjects receiving concurrent
treatment with drugs that could contribute to hypothyroidism,
and subjects receiving antithyroid drugs presumably for
hyperthyroidism.
All secondary cases of hypothyroidism and subjects inwhom
kidney functions could not be estimated because of missing
serum creatinine values or those in whom TSH or FT4 levels
were not available were also excluded.
Statistical analysis
Data were analyzed using SPSS 16 (IBM Corporation, New
York, USA). The Student t test, analysis of variance (one way),
ManneWhitney test for scattered data were performed, and
odds ratio with 95% conﬁdence interval is reported. A P value
< 0.05 was considered signiﬁcant.
Results
Study population
A total of 1,863 adult participants had valid serum creatinine
measurements and eGFR. Among 1,863 CKD patients seen inthe nephrology out patient department, 358 patients under-
went biochemical analysis for hypothyroidism. Among these,
156 had normal TSH values (between 0.35 and 5.5 mIU/L),
whereas 143 had biochemical SCH (i.e., TSH > 5.5 mIU/L with
normal FT4 levels), and 59 had overt hypothyroidism (i.e., TSH
> 5.5 mIU/L with FT4 levels < 0.89 ng/dL). The prevalence of
subclinical and overt primary hypothyroidism together in the
total CKD population was 10.84%, whereas it was 56.42% in the
subjects tested for hypothyroidism (Fig. 1 and Table 1).
The mean age was 55.89 ± 12.85 and 55.16 ± 14.28 years in
the subclinical and overt hypothyroidism groups, respectively.
Characteristics of persons with and without prevalent
hypothyroidism
Overall, individuals with clinical hypothyroidism and SCH
were roughly of the same age (Table 2). In gender distribution
between the groups, the number of menwas higher in the overt
hypothyroid group although nonsigniﬁcant. In the subclinical
hypothyroid group, both the sexes were almost equally
distributed. Systolic blood pressure was signiﬁcantly higher in
overt and subclinical hypothyroid groups compared to the
nonhypothyroid group (P < 0.001).
FT4 concentrations differed signiﬁcantly among the
overt, subclinical hypothyroid, and nonhypothyroid groups
(0.7 ± 0.1, 1.2 ± 0.2, and 1.3 ± 0.2 mIU/L, respectively, P¼ 0.001).
Mean spot urine protein of 134.8 ± 129.8 mg/dL (median
100 mg/dL) was signiﬁcantly higher in the overt hypothyroid
group (P < 0.02). Patients with hypothyroidism (both clinical
and subclinical) had signiﬁcantly lower serum albumin
(P ¼ 0.00) and serum calcium levels (P ¼ 0.002) than those in
the nonhypothyroid group. Intact parathyroid hormone (PTH)
was also signiﬁcantly higher in the hypothyroid groups than in
the nonhypothyroid group (P¼ 0.001). Hemoglobin levels were
lower in the hypothyroid groups than in the nonhypothyroid
group although it was not signiﬁcant (P ¼ 0.068). The patients
in the hypothyroid groups (both clinical and subclinical) also
had higher BMI compared with patients in the nonhypothyroid
group (24.7 ± 6.5 vs. 23.0 ± 5.8). No signiﬁcant difference was
seen in the lipid proﬁle among all the groups.
Table 1. Prevalence of subclinical and overt hypothyroidism in different stages of GFR
GFR Primary hypothyroidism (n ¼ 59), N (%) Subclinical hypothyroidism (n ¼ 143), N (%) Nonhypothyroid (n ¼ 202), N (%)
2 4 (6.78) 16 (11.19) 20 (12.82)
3a 1 (1.69) 14 (9.79) 14 (8.97)
3b 6 (10.18) 25 (17.48) 48 (30.77)
4 24 (40.68) 41 (28.67) 26 (16.68)
5 24 (40.68) 47 (32.84) 48 (30.76)
Total 59 143 202
GFR, glomerular ﬁltration rate.
Table 2. Comparison of different variables in overt hypothyroidism, subclinical hypothyroidism, and nonhypothyroids
Variable Primary hypothyroidism (n ¼ 59) Subclinical hypothyroidism (n ¼ 143) Nonhypothyroid (n ¼ 156)
Age (y) 55.2 ± 14.3 55.9 ± 12.9 55.0 ± 14.4
Sex (M, F) 37, 22 71, 72 112, 44
Comorbidities
Diabetes mellitus 18 (30.51) 83 (58.04) 70 (44.87)
Hypertension 43 (72.88) 127 (88.81) 120 (76.92)
CAD 3 (5.08) 4 (2.79) 4 (2.56)
COPD 0 3 (2.1) 2 (1.28)
CVA 0 2 (1.28)
BMI 25.2 ± 4.4 24.1 ± 7.8 23.0 ± 5.8
SBP (mmHg) 147.2 ± 24.6 157.0 ± 26.3 134.0 ± 16.5
DBP (mmHg) 84.5 ± 11.6 88.0 ± 7.7 88.0 ± 9.4
TSH 83.0 ± 105.0 9.0 ± 4.4 2.0 ± 0.9
Free T4 0.7 ± 0.1 1.2 ± 0.1 1.3 ± 0.2
Triglyceride (mg/dL) 168.5 ± 103.8 153.0 ± 86.4 169.2 ± 95.6
Total cholesterol (mg/dL) 141.9 ± 74.5 159.7 ± 59.9 161.4 ± 48.4
Hemoglobin (g/dL) 9.6 ± 2.3 9.7 ± 1.9 10.1 ± 2.2
Serum calcium (mg/dL) 8.3 ± 0.9 8.7 ± 0.9 8.9 ± 0.8
Serum albumin (g/dL) 3.7 ± 0.7 3.6 ± 0.6 3.8 ± 0.5
Phosphorus (mg/dL) 5.2 ± 2.2 4.6 ± 1.6 5.0 ± 1.3
SALP (U/L) 141.2 ± 64.7 145.6 ± 82.6 168.3 ± 51.1
iPTH (ng/L) 236.1 ± 195.6 (median ¼ 156) 183.5 ± 190.4 (median ¼ 161.6) 39.2 ± 80.2 (median ¼ 23.67)
Urine proteinuria (mg/dl) 134.8 ± 129.8 (median ¼ 100) 113.2 ± 131.9 (median ¼ 100) 79.5 ± 96.5 (median ¼ 30)
Data are presented as n (%) or mean ± SD.
BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DBP, diastolic
blood pressure; iPTH, intact parathyroid hormone; SALP, serum alkaline phosphatase; SBP, systolic blood pressure; SD, standard deviation; TSH,
thyroid-stimulating hormone.
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followed by diabetes mellitus across all groups.
Kidney function and prevalent hypothyroidism
We observed that the prevalence of hypothyroidism was
increased in subjects with reduced GFR, ranging from 32.68%
for persons with eGFR  30 mL/min/1.73 m2 to 67.32% in pa-
tients with eGFR < 30 mL/min/1.73 m2. Compared with GFR
 60 mL/min/1.73 m2, the odds of hypothyroidism increased
among subjects with lower eGFR: adjusted odds ratio, 1.07 (95%
conﬁdence interval, 0.41e2.78) for an GFR of 45e59 mL/min/
1.73 m2, 0.65 (0.29e1.39) for an GFR of 30e44 mL/min/1.73 m2,
2.5 (1.16e5.39) for an GFR of 30e15 mL/min/1.73 m2, and 1.48
(0.72e3.74) for an GFR of < 15 mL/min/1.73 m2.
Discussion
Thyroid autoimmunity and subclinical primary hypothy-
roidism are highly prevalent in CKD patients not requiring
long-term dialysis treatment [3]. In their study, Lo et al [2] re-
ported a prevalence of hypothyroidism of 23.1% in CKD patients
with an eGFR < 30 mL/min/1.73 m2. In another study, subclin-
ical hypothyroidism and clinically apparent hypothyroidism
have been reported to occur in ~18e20% of patients with CKD
not requiring renal replacement therapy [1]. This study differsfrom these previous observations by demonstrating a preva-
lence of subclinical and overt primary hypothyroidism (10.8%).
An increased prevalence of subclinical and overt primary hy-
pothyroidism in persons with reduced eGFR independent of
age and gender was seen in this study. This is in line with the
observation made by Chonchol et al [1]. In this study, the ab-
solute prevalence of hypothyroidism in the lower GFRs is
higher than that reported in other studies, whichmay be due to
the smaller sample size in the present study. Majority of the
patients in this study fell in the CKD stage 4/5 category, which
could be due to the fact that most of the CKD patients referred
to this tertiary care center have a low GFR. A multicentric
screening program for hypothyroidism in the CKD population
can provide a better picture of its actual prevalence.
Higher TSH levels are seenwith increasing age [4]. Themean
age in this study was 55.2 ± 14.3 and 55.9 ± 12.9 years in
subclinical and overt hypothyroidism groups, respectively.
The TSH level is often elevated in CKD in response to
thyrotropin from pituitary as a result of uremic effect [5]. TSH
also loses its circadian rhythm along with compromised
bioactivity due to poor glycosylation. Chronic metabolic
acidosis has also been labeled as one of the contributing factors
in the rise of hypothyroidism cases in CKD population [6]. The
WolffeChaikoff effect [7] has been cited as a causative phe-
nomenon behind the rise of this disorder in diabetic kidney
disease patients. In our study, diabetes mellitus was present in
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ism and SCH, respectively, although it was not signiﬁcantly
different from the nonhypothyroid group.
Dyslipidemia is seen throughout the spectrum of thyroid
dysfunction although it is of much milder degree with TSH
levels between 5 and 10 mU/L compared to TSH > 10 mIU/L
[8e10]. A few reports [11,12] have shown signiﬁcantly elevated
total cholesterol with TSH < 10 mIU/L in comparison to eu-
thyroids. Contrary to this, total cholesterol and triglyceride
levels were not signiﬁcantly different in hypothyroids (overt
and subclinical) compared to nonhypothyroids in our study.
Inagreement toour study, Shanthaetal [13]havealsoreported
lower serum albumin levels in this population. Higher degree of
proteinuria in the hypothyroid group can explain this ﬁnding.
An increase in TSH levels may lead to increase in PTH levels
either due to thyrotropin-releasing hormone stimulation or
error in measurement by immunometric assays [14]. Our study
followed the trend. Hypothyroidism leads to a reduction of
osteoclast bone reabsorption and osteoblast formation, slowing
the remodeling process and increasing the time taken in the
remodeling cycle, mainly due to the prolongation of the
mineralization phase. A slight increase in bone mass may occur,
albeit not with a reduced risk of fracture.
The incidence of anemia in hypothyroidism ranges between
23% and 60%. It is generally multifactorial. Hypothyroidism
induces a decrease in bone marrow volume along with a
decrease in nucleated blood cell precursors [15e17]. A decrease
in gastric acid production in the hypothyroid state leads to a fall
in iron absorption causing iron-deﬁciency anemia [18].
Increased blood loss due to menorrhagia may also lead to iron
deﬁciency. Folate deﬁciency and higher incidence of pernicious
anemia [19] may lead to macrocytic anemia. In our study, he-
moglobin levels were also lower in subclinical and hypothyroid
groups but not independent of GFR.
Our study also had several limitations. This is a cross-
sectional study, so causality cannot be established. As this
study was not based on screening, our observations may have
underestimated the true prevalence of hypothyroidism in CKD.
In addition, our study lacks details about the possible etiology
of SCH or a measure of antithyroid antibodies. A prospective
study is desirable, which can throw light on the effect of
thyroxine treatment on GFR and give a better picture of the true
prevalence of hypothyroidism in CKD population.Conﬂicts of interest
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